Damloran Pharmaceutical (XTEH:DAML1) Return-on-Tangible-Equity: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTEH:DAML1 Damloran Pharmaceutical XTEH:DAML1
27 GF Score
Price IRR10,100.00
View Full Analysis

What is Damloran Pharmaceutical Return-on-Tangible-Equity?

Damloran Pharmaceutical XTEH:DAML1 27 Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus rates XTEH:DAML1 with a GF Score™ of 27/100.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Damloran Pharmaceutical's annualized net income for the quarter that ended in . 20 was IRR Mil. Damloran Pharmaceutical's average shareholder tangible equity for the quarter that ended in . 20 was IRR Mil. Therefore, Damloran Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 was %.

The historical rank and industry rank for Damloran Pharmaceutical's Return-on-Tangible-Equity or its related term are showing as below:

XTEH:DAML1's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.895
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Damloran Pharmaceutical  (XTEH:DAML1) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.

Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.

Damloran Pharmaceutical Return-on-Tangible-Equity Related Terms

Damloran Pharmaceutical Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Damloran Pharmaceutical's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Damloran Pharmaceutical Return-on-Tangible-Equity Chart

Damloran Pharmaceutical Annual Data
Trend
Return-on-Tangible-Equity

Damloran Pharmaceutical Semi-Annual Data
Return-on-Tangible-Equity

XTEH:DAML1 vs IMNPQ: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Damloran Pharmaceutical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Damloran Pharmaceutical Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Damloran Pharmaceutical's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Damloran Pharmaceutical's Return-on-Tangible-Equity falls into.


XTEH:DAML1
27GF Score
Damloran Pharmaceutical XTEH:DAML1
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Damloran Pharmaceutical Return-on-Tangible-Equity Calculation

Damloran Pharmaceutical's annualized Return-on-Tangible-Equity for the fiscal year that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( (+ )/ )
=/
= %

Damloran Pharmaceutical's annualized Return-on-Tangible-Equity for the quarter that ended in . 20 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Damloran Pharmaceutical (XTEH:DAML1) has a Return-on-Tangible-Equity of 0.00% as of . 20. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Damloran Pharmaceutical and its competitors.
Is Damloran Pharmaceutical's Return-on-Tangible-Equity too high?
Damloran Pharmaceutical's current Return-on-Tangible-Equity is 0.00%. Overall, Damloran Pharmaceutical has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Damloran Pharmaceutical's Return-on-Tangible-Equity compare to IMNPQ?
Damloran Pharmaceutical's Return-on-Tangible-Equity of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 900 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Damloran Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Damloran Pharmaceutical's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Damloran Pharmaceutical stock overvalued right now?
Damloran Pharmaceutical (XTEH:DAML1) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Damloran Pharmaceutical's overall GF Score™ is 27/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Damloran Pharmaceutical (XTEH:DAML1), the current Return-on-Tangible-Equity is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Damloran Pharmaceutical Business Description

Address No.4, Parvin Alley, West Fatemi Avenue, Tehran, IRN
Damloran Pharmaceutical manufactures and markets livestock and poultry pharmaceuticals. The Company offers animal health products to protect and improve health and hygiene of society to treat and to enhance the quality of animals' life.
27GF Score

Get the complete analysis for XTEH:DAML1

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

IRR10,100.00
Price